UNIHEALTH — Unihealth Hospitals Income Statement
0.000.00%
- IN₹5.20bn
- IN₹5.83bn
- IN₹555.88m
- 35
- 28
- 93
- 52
Annual income statement for Unihealth Hospitals, fiscal year end - March 31st, INR millions except per share, conversion factor applied.
2021 March 31st | 2022 March 31st | 2023 March 31st | 2024 March 31st | 2025 March 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | PROSPECTUS | ARS | ARS |
| Standards: | IAS | IAS | IAS | IAS | IAS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 262 | 368 | 439 | 488 | 556 |
| Cost of Revenue | |||||
| Gross Profit | 200 | 284 | 367 | 401 | 426 |
| Selling / General / Administrative Expenses | |||||
| Depreciation and Amortization | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 196 | 252 | 293 | 278 | 344 |
| Operating Profit | 66 | 117 | 147 | 210 | 212 |
| Gain / Loss on Sale of Assets | |||||
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | 54.7 | 52 | 92.8 | 136 | 173 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | 49.5 | 37.9 | 76.6 | 104 | 151 |
| Minority Interest | |||||
| Equity in Affiliates | |||||
| Net Income Before Extraordinary Items | |||||
| Net Income | 50.1 | 38.2 | 76.8 | 103 | 151 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | 50.1 | 38.2 | 76.8 | 103 | 151 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | 3.25 | 2.48 | 4.97 | 7.67 | 9.83 |
| Dividends per Share |